Serum visfatin and omentin levels in slow coronary flow | Zendy

Taner Uçgun | Zendy; Cengiz Başar | Zendy; Ramazan Memişoğulları | Zendy; Hilmi Demirin | Zendy; Yasin Türker | Zendy; Yusuf Aslantaş | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum visfatin and omentin levels in slow coronary flow

Author(s) -

Taner Uçgun,

Cengiz Başar,

Ramazan Memişoğulları,

Hilmi Demirin,

Yasin Türker,

Yusuf Aslantaş

Publication year - 2014

Publication title -

revista portuguesa de cardiologia

Language(s) - English

Resource type - Journals

eISSN - 2174-2030

pISSN - 0870-2551

DOI - 10.1016/j.repc.2014.04.007

Subject(s) - adipokine , medicine , timi , coronary artery disease , cardiology , proinflammatory cytokine , pathophysiology , inflammation , endothelial dysfunction , endocrinology , pathogenesis , adiponectin , gastroenterology , myocardial infarction , leptin , obesity , insulin resistance , thrombolysis

The adipocytokines visfatin and omentin have a direct effect on inflammation and endothelial injury. The expression of visfatin is closely associated with the expression of proinflammatory cytokines. Omentin has an anti-inflammatory effect and is inversely associated with coronary artery disease (CAD). The slow coronary flow phenomenon is an angiographic finding characterized by delayed distal vessel opacification in the absence of significant epicardial coronary disease. The pathophysiology of SCF has not been clearly identified, although multiple abnormalities including endothelial dysfunction, atherothrombosis and inflammation have been reported. However, the relationship between visfatin, omentin and SCF is still unknown. In this study, we aimed to investigate the relationship of these adipocytokines with SCF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research